Comparison of intravenous immunoglobulin formulations: Product, formulary, and cost considerations

Hospital Pharmacy

Volumn 46, Issue 9, 2011, Pages 668-676

  Mark, Scott M ^a  

^a ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

cost; formulary considerations; intravenous immunoglobulin; physicochemical properties; stability; tolerability

Indexed keywords

CARIMUNE NF; EXCIPIENT; GAMMAPLEX; GLYCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; PROLINE; SODIUM; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BONE MARROW TRANSPLANTATION; DRUG COST; DRUG EFFICACY; DRUG FORMULARY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FLUSHING; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; NAUSEA; ORGAN TRANSPLANTATION; OSMOLALITY; REVIEW; RIGOR; SIDE EFFECT;

EID: 80052539258     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4609-668     Document Type: Review

References (55)

1. Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94:S1-63.
2. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010; 24(Suppl 1):S28-50.
3. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immune globulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl 1): S525-553.
4. Ontario Regional Blood Coordinating Network (ORBCoN). Ontario Intravenous Immune Globulin (IVIG) Utilization Management Guidelines. November 5, 2009. http://www. transfusionontario.org/media/IVIG%20GuidelinesFINAL.pdf. Accessed June 24, 2011.
5. Jolles S, SewellWA,Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005;142:1-11. (Pubitemid 41360999)
6. Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003;3: 653-64. (Pubitemid 36745237)
7. Yamani MH, Avery R, Mawhorter S, et al. Hypogammaglobulinemia after heart transplantation: impact of preemptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transplant Infect Dis. 2001; 3(Suppl 2):40-3. (Pubitemid 34073655)
8. Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1-10.
9. Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1-7. (Pubitemid 38781052)
10. Stucki M, Boschetti N, Schafer W, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals. 2008;36:239-247.
11. Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production, methods, quality control and quality assurance. Vox Sang. 2010;98:12-28.
12. Gelfand EW. Differences between IVIG products: impact on clinical outcome. Int Immunopharmacol. 2006;6:595-599.
13. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm. 2005;62(Suppl 3):S5-11. (Pubitemid 41153671)
14. Siegel J. The product: all intravenous immunoglobulins are not equivalent. Pharmacotherapy. 2005;25(11 Pt 2):78S-84S. (Pubitemid 41566908)
15. Cramer M, Frei R, Sebald A, et al. Stability over 36 months of a new liquid 10% polyclonal immunoglobulin product (IgPro10, Privigen) stabilized with L-proline. Vox Sang. 2009; 96:219-25.
16. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43: 1460-1480. (Pubitemid 37322509)
17. Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev. 2003;17:241-251. (Pubitemid 37310931)
18. Gaines A, Varricchio F, Kapit R, et al. Renal insufficiency and failure associated with globulin intravenous therapy. Morb Mortal Wkly Rep. 1999;48:518-521.
19. Bolli R, Woodtli K, Bärtschi M, Höfferer L, et al. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010; 38:150-157.
20. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia: detection of IgE antibodies to IgA. N Engl J Med. 1986;314:560-564. (Pubitemid 16128065)
21. Manlhiot C, Tyrrell PN, Liang L, et al. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Pediatrics. 2008;121:e626-630.
22. Carimune NF (immune globulin intravenous [human]) [package insert]. King of Prussia, PA: CSL Behring LLC; 2005.
23. Gammagard Liquid 10% (immune globulin intravenous [human]) [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2005.
24. Gammagard S/D (immune globulin intravenous [human]) [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2008.
25. Gammaplex 5% (immune globulin intravenous [human]) [package insert]. Elstree, Hertfordshire, UK: Bio Products Laboratory; 2010.
26. Gamunex 10% (immune globulin intravenous [human]) [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics, Inc; 2008.
27. Privigen 10% (immune globulin intravenous [human] [package insert]. King of Prussia, PA: CSL Behring LLC; 2007.
28. Prins C, Gelfand EW, French LE. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology. Acta Derm Venerol. 2007;87:206-218. (Pubitemid 47226887)
29. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet. 1992;339:682-684.
30. Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharm Pract News. 2010;37:1-10.
31. Berger M; Flebogamma 5% DIF Investigators. A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of Flebogamma. J Clin Immunol. 2007;27:628-633.
32. FDA Draft Guidance for Industry. Safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. November 2005. http://www.fda.gov/BiologicsBloodVaccines/GuidanceCompliance RegulatoryInformation/Guidances/Blood/ucm072130.html. Accessed March 8, 2010.
33. Ochs HD, Pinciaro PJ; Octagam Study Group. Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol. 2004;24:309-314. (Pubitemid 39030679)
34. Debes A, Bauer M, Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf. 2007;16: 1038-1047. (Pubitemid 47422854)
35. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. Int Immunopharmacol. 2003;3:1325-1333. (Pubitemid 36936768)
36. Ballow M, Berger M, Bonilla FA, et al. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). Vox Sang. 2003;84: 202-210. (Pubitemid 36514177)
37. Church JA, Leibl H, Stein MR, et al; US-PID-IGIV 10% -Study Group10. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26:388-395. (Pubitemid 44051386)
38. Björkander J, Nikoskelainen J, Leibl H, et al. Prospective open-label study of pharmacokinetics, efficacy and safety of a new 10% liquid intravenous immunoglobulin in patients with hypo- or agammaglobulinemia. Vox Sang. 2006;90:286-293.
39. Stein MR, Nelson RP, Church JA, et al. Safety and efficacy of Privigen, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies. J Clin Immunol. 2009;29:137-144.
40. Berger M, Cunningham-Rundles C, Bonilla FA, et al. Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. J Clin Immunol. 2007;27:503-509. (Pubitemid 47319249)
41. Wittstock M, Benecke R, Zettl UK. Therapy with intravenous immunoglobulins: complications and side-effects. Eur Neurol. 2003;50:172-175. (Pubitemid 37256053)
42. Brennan VM, Salomé-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibodydeficient patients receiving intravenous immunoglobulin. Clin Exp Immunol. 2003;133:247-251. (Pubitemid 36918599)
43. Ameratunga R, Sinclair J, Kolbe J. Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004;136:111-113. (Pubitemid 38437772)
44. Kallenberg CGM, Laseur M. Cost considerations in choosing an intravenous immunoglobulin preparation. EJHP Pract. 2007;2:66-68.
45. Flebogamma 5% DIF (immune globulin intravenous [human]) [package insert]. Los Angeles, CA: Grifols Biologicals, Inc; 2006.
46. Kallenberg CGM. A 10% ready-to-use intravenous human immunoglobulin offers potential economic advantages over a lyophilized product in the treatment of primary immunodeficiency. Clin Exp Immunol. 2007;150:437-441. (Pubitemid 350098742)
47. Mahadevia PJ, Strell J, Kunaprayoon D, et al. Cost savings from intravenous immunoglobulin manufactured from chromotography/caprylate (IGIV-C) in persons with primary humoral immunodeficiency disorder. Value Health. 2005;8:488-494. (Pubitemid 41726102)
48. Boyle ML, Scalchunes C. Impact of intervenous immunoglobulin (IGIV) treatment among patients with primary immunodeficiency diseases. Pharm Policy Law. 2008;10:133-146.
49. Octagam 5% (immune globulin intravenous [human]) [package insert]. Centreville, VA: Octapharma USA, Inc; 2006.
50. Vivaglobin 16% (immune globulin subcutaneous [human]) [package insert]. King of Prussia, PA: CSL Behring LLC; 2007.
51. Hizentra 20% (immune globulin subcutaneous [human]) [package insert]. King of Prussia, PA: CSL Behring LLC; 2007.
52. Siegel J. Immunoglobulins and obesity. Pharm Pract News. 2010;37:1-4.
53. Office for Science and Data Policy. Analysis of supply, distribution, demand, and access issues associated with immune globulin intravenous (IGIV). Washington, DC: US Department of Health and Human Services; February 2007.
54. Immune Deficiency Foundation. Treatment Experiences and Preferences of Patients with Primary Immune Deficiency Diseases: First National Survey. Towson, MD: Author; 2003.
55. American Academy of Allergy, Asthma & Immunology. Eight guiding principles for safe, effective and appropriate use of IGIV 2006. www.clinimmsoc.org/teaching/downloads/IGIV-coverage.pdf. Accessed March 2010.